5 November 2026
2QFY27 Results Update | Sector: Consumer

Emami

Estimate change	⟷
TP change	↓
Rating change	⟷

Bloomberg	HMN IN
Equity Shares (m)	437
M.Cap.(INRb)/(USDb)	169.4 / 1.8
52-Week Range (INR)	551 / 357
1, 6, 12 Rel. Per (%)	-5/-17/-23
12M Avg Val (INR M)	386

Financials & Valuations (INR b)

Y/E March	2027E	2028E	2029E
Sales	45.5	50.5	55.8
Sales Gr. (%)	20.4	10.9	10.6
EBITDA	10.8	12.4	14.6
EBITDA Margin (%)	23.8	24.7	26.1
Adj. PAT	8.3	9.2	10.7
Adj. EPS (INR)	18.9	21.0	24.5
EPS Gr. (%)	-3.5	10.8	17.0
BV/Sh.(INR)	72.9	79.4	87.9
Ratios			
RoE (%)	27.1	27.5	29.3
RoCE (%)	30.8	30.7	32.6
Payout (%)	60.7	62.0	59.1
Valuation			
P/E (x)	20.5	18.5	15.8
P/BV (x)	10.0	9.2	8.3
EV/EBITDA (x)	28.1	24.3	20.5
Div. Yield (%)	3.0	3.4	3.7

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	54.8	54.8	54.8
DII	23.6	27.0	25.0
FII	9.0	7.9	10.9
Others	12.6	10.3	9.2

FII Includes depository receipts

CMP: INR388 **TP: INR475 (+22%)** **Buy**

Positive growth delivery; cost pressure persists

- Emami's consolidated revenue grew 36% YoY to INR10.8b (24% LFL; beat) in 2QFY27, aided by the consolidation of Axiom Ayurveda and IncNut Digital. Domestic business delivered 49% revenue growth, with LFL revenue/volume growth of 32%/26%, on a weak base of -15%/-16% in 2QFY26 (GST transition). The strong recovery in underlying volumes is encouraging, although the low base aided growth. Management expects total business growth of 18-20% in 2HFY27, supported by sustained momentum across core brands and strategic investments.
- Hair Care and Skin Care delivered strong growth of 30% and 31%, respectively, while Healthcare grew 11%. The strategic investment portfolio recorded 73% LFL growth, with its contribution to domestic revenue rising to ~26% from ~18% in 1Q. International business declined 2% YoY, but management gave positive guidance for FY27. Management expects the international business recovery to strengthen over the coming quarters.
- Gross margin contracted sharply by 520bp YoY to 65.8%, with raw material inflation accounting for ~400bp of the decline and the balance attributable to the changing business mix following acquisitions. Consequently, EBITDA margin contracted 190bp YoY to 20.4%. EBITDA grew 25% YoY to INR2.2b (beat), supported by robust topline growth. Emami has implemented ~5.5% price increases to fully offset input cost inflation. The company expects elevated inventory costs to sustain margin pressure through 2HFY27, with meaningful RM cost relief expected only in FY28. We expect EBITDA growth to be 13-15% in FY27/FY28.
- Domestic demand momentum strengthened, with 26% underlying volume growth, albeit on a weak base. The strategic investment portfolio continues to scale rapidly, providing an increasingly meaningful growth lever. We believe elevated input costs and higher brand investments are likely to keep margins under pressure through 2HFY27. Emami's calibrated pricing actions and productivity initiatives should aid gradual margin recovery going ahead. **Given its reasonable valuations of 19x/16x FY28/FY29 EPS, we reiterate our BUY rating with a TP of INR475 (based on 20x on Sep'28 EPS).**

Strong print; organic volume up 26%

- **Strong organic growth:** Consolidated net sales grew 36% YoY to INR10.8b (24% LFL; est. INR9.6b), aided by the acquisition of Axiom Ayurveda and IncNut Digital. Domestic revenue grew 49% YoY, with LFL revenue/volume growth of 32%/26%, on a weak base of -15%/-16% in 2QFY26, indicating a healthy recovery in underlying demand. International business declined 2% YoY, although it grew 6% excluding Nepal and Iraq, reflecting improving momentum across key markets.

Naveen Trivedi – Research Analyst (Naveen.Trivedi@motilaloswal.com
Research Analyst: Amey Tiwari (Amey.Tiwari@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.
MotilalOswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Strategic portfolio continues with its strong momentum:** The strategic investments portfolio grew 73% on an LFL basis and now contributes 26% of domestic revenue (~18% in 1QFY27). Hair Care and Skin Care grew 30%/31%, while Healthcare grew 11%. Within the core portfolio, Cool Oils grew in the thirties, Kesh King in the high teens and BoroPlus in the twenties. Talc and Prickly Heat powder sales more than doubled, while Pain Management grew in the teens. Emami is also boosting its innovation pipeline, with the launch of the FromMaa baby care range and increased focus on sunscreen and shower gel.
- **EBITDA grow 25% YoY in 2Q:** Gross margin contracted 520bp YoY to 65.8% (est. 66.5%), remaining the key drag on operating profitability. Employee expenses, advertising spend, and other expenses increased 16%/38%/24%, respectively, reflecting higher brand investments and operating costs. Consequently, EBITDA margin contracted 190bp YoY to 20.4% (in line). Nevertheless, strong revenue growth aided 25% YoY EBITDA growth to INR2.2b (est. INR2b), despite RM pressure.
- **Higher tax limits PAT growth:** PBT (before exceptional items) grew 28% YoY to INR2b (est. INR1.7b), supported by strong operating performance. However, the effective tax rate stood at 25% versus our expectation of 18%, largely due to the normalization of tax rates following the phase-out of fiscal benefits. Consequently, APAT declined 6% YoY to INR1.6b (est. INR1.5b).

Key highlights from the management commentary

- Rural demand was mixed. South, West and parts of UP lagged due to deficient rainfall, while districts with good rainfall did well. Demand should pick up post-Diwali as winter, the portfolio's peak season, sets in.
- **The company has implemented price increases of ~5.5% for FY27 and has fully passed through input cost inflation.**
- **The company guided for total business growth is guided at 18-20% for 2HFY27, as momentum across core brands and strategic investments continues.**
- Organized channels contributed 37% of domestic business (32% in 1QFY27), with MT and e-commerce maintaining strong momentum.
- Quick commerce accounted for ~15% of total digital sales.
- Emami's effective tax rate normalized to ~25% (compared with the previous year's MAT credit utilization/entitlement).

Valuation and view

- We trim our EPS estimated by 1-2% for FY27 and FY28.
- Emami's sharp recovery in domestic volumes, sustained momentum across core brands and rapid scaling of its strategic investment portfolio strengthen its medium-term growth outlook. The increasing salience of the strategic portfolio contribution to domestic revenue reinforces confidence in its emerging growth engines. Moreover, Emami continues to strengthen its distribution reach predominantly through alternate channels (MT, e-com, and QC).
- While elevated input costs and higher brand investments are likely to defer margin recovery to FY28, we believe the improving growth trajectory is adequately captured in the stock's valuation of 19x/16x FY28/FY29 EPS. **We reiterate our BUY rating with a TP of INR475 (based on 20x Sep'28E EPS).**

Consol. Quarterly performance (INR m)

Y/E MARCH	FY26				FY27E				FY26	FY27E	FY27E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Domestic volume gr. (%)	-3.0	-16.0	9.0	-7.0	16.0	43.0	12.0	12.0	-4.3	20.8	16.0	
Net Sales	**9,041**	**7,985**	**11,518**	**9,251**	**10,392**	**10,877**	**13,514**	**10,740**	**37,795**	**45,522**	**9,577**	13.6%
YoY change (%)	-0.2	-10.3	9.8	-3.9	14.9	36.2	17.3	16.1	-0.8	20.4	19.9	
Gross Profit	**6,276**	**5,671**	**8,136**	**6,332**	**6,840**	**7,159**	**9,054**	**7,219**	**26,415**	**30,272**	**6,369**	12.4%
Gross margin (%)	69.4	71.0	70.6	68.4	65.8	65.8	67.0	67.2	69.9	66.5	66.5	
EBITDA	**2,142**	**1,785**	**3,842**	**1,867**	**2,262**	**2,223**	**4,225**	**2,137**	**9,637**	**10,847**	**1,955**	13.7%
Margins (%)	23.7	22.4	33.4	20.2	21.8	20.4	31.3	19.9	25.5	23.8	20.4	
YoY change	-1.1	-28.7	13.4	-14.9	5.6	24.5	10.0	14.4	-6.0	12.6	9.5	
Depreciation	445	453	453	423	428	453	460	498	1,773	1,839	466	
Interest	24	26	29	32	56	61	55	53	111	180	25	
Other Income	216	214	190	232	185	230	210	246	851	870	218	
PBT	**1,889**	**1,520**	**3,549**	**1,645**	**1,963**	**1,939**	**3,920**	**1,831**	**8,603**	**9,699**	**1,683**	15.2%
Tax	225	18	256	209	558	481	706	283	708	2,027	303	
Rate (%)	11.9	1.2	7.2	12.7	28.4	24.8	18.0	15.4	8.2	20.9	18.0	
Adj. PAT	**1,843**	**1,711**	**3,408**	**1,603**	**1,524**	**1,611**	**3,374**	**1,710**	**8,565**	**8,265**	**1,556**	3.6%
YoY change (%)	8.3	-26.7	13.4	-11.6	-17.3	-5.8	-1.0	6.7	-3.3	-3.5	-9.1	
Reported PAT	**1,643**	**1,484**	**3,195**	**1,432**	**1,389**	**1,455**	**3,202**	**1,529**	**7,753**	**7,620**	**1,367**	6.4%
YoY change (%)	9.1	-29.7	14.5	-11.7	-15.4	-1.9	0.2	6.8	-3.4	-1.7	-7.9	

E: MOFSL Estimates



Key highlights from the management commentary

Performance and outlook

- The operating environment stayed challenging with West Asia tensions, Nepal floods, persistent commodity inflation and deficient rainfall. That said, growth was partly aided by a soft 2QFY26 base (GST transition).
- Rural demand was mixed. South, West and parts of UP lagged on deficient rainfall, while districts with good rainfall did well. Demand should pick up post Diwali as winter, the portfolio's peak season, sets in.
- Price increases of ~5.5% for FY27, the company has fully passed through input cost inflation.
- Total business growth is guided at 18-20% for 2HFY27, as momentum across core brands and strategic investments continues.
- FY27 revenue guidance for strategic investments was raised to INR8.5-8.8b from INR7.5-8b, implying an exit run-rate of INR10-11b.
- SalesCode.AI and Project SETU (supply chain) are slightly ahead of schedule. Completion is targeted in 4QFY27, with tangible gains from FY28. The current pilots in select markets show encouraging results.

Cost and margins

- Gross margin contracted 520bp YoY to 65.8%. Of the impact, ~400bp came from raw material inflation and the rest from mix shift toward the lower-margin acquired businesses.
- Emami indicated that Input costs to stay elevated in 2HFY27, because of high cost inventory. The benefit of any input cost correction is likely only in FY28.
- FY27 A&P is guided at 18-19%, with spending prioritized behind growth over near-term margin.
- Effective tax rate normalized to ~25% (MAT credit utilization vs entitlement last year).

Channel-wise performance

- Organized channels contributed 37% of domestic business (32% in 1QFY27), with MT and e-commerce maintaining strong momentum.
- Quick commerce accounted for ~15% of total digital sales.
- Axiom expanded into MT chains and entered quick commerce.
- IncNut is expanding beyond D2C into marketplaces, quick commerce and new international markets.

Segment performance

- Skin Care grew 31% (21% of domestic), led by talc sales more than doubling. BoroPlus grew in the near-20s, and Smart & Handsome posted double-digit growth after its Sep'26 restaging.
- Hair & Scalp Care grew 30% (~22% of domestic). Navratna cool oils grew in the 30s, Kesh King in the high teens, and 7 Oils in One nearly doubled.
- Healthcare grew 11% (31% of domestic): pain management in the teens, OTC in the high teens and Medico in single digits.
- Strategic investments grew 73% like-to-like (61% in 1Q) and contributed ~26% of domestic business. Axiom and Brillare more than doubled, IncNut grew 50%+ and TMC 30%+.
- BoroPlus FromMaa marks entry into baby care, an INR300-400b market. It is priced 25-50% below competitors with mass positioning and launches first on e-commerce and MT.
- Kesh King Scalp First is a premium, ingredient-led extension priced at INR500-1,000, launched in MT and e-commerce. It takes the brand upmarket while staying priced below premium international and D2C peers.

International performance

- International business declined 2% YoY to INR1.7b (16% of consolidated) but grew 6% excluding Nepal and Iraq; 1H declined 7%.
- Nepal was hit by severe floods. Iraq saw near-zero sales because goods could not be moved, though alternate routes have since been found.
- Bangladesh and GCC have turned around. Growth has been positive for the last three months, with October at high double digits, indicating the worst is behind.
- Emami is mitigating the international supply chain issues through alternate shipping routes, container-load optimization, disciplined spending and price increases across most markets.

Key Exhibits

Exhibit 1: Domestic volumes grew 43% YoY in 2QFY27 (with acquisitions, LFL volume growth at 26%)




Exhibit 2: Consolidated net sales grew 36% YoY to INR10.9b




Exhibit 3: Gross margin contracted 520bp YoY to 65.8%




Exhibit 4: EBITDA margin contracted 190bp YoY to 20.4%





Exhibit 5: EBITDA grew 25% YoY to INR2.2b in 2QFY27



Valuation and view

- We trim our EPS estimated by 1-2% for FY27 and FY28.
- Emami's sharp recovery in domestic volumes, sustained momentum across core brands and rapid scaling of its strategic investment portfolio strengthen its medium-term growth outlook. The increasing salience of the strategic portfolio contribution to domestic revenue reinforces confidence in its emerging growth engines. Moreover, Emami continues to strengthen its distribution reach predominantly through alternate channels (MT, e-com, and QC).


- While elevated input costs and higher brand investments are likely to defer margin recovery to FY28, we believe the improving growth trajectory is adequately captured in the stock's valuation of 19x/16x FY28/FY29 EPS. **We reiterate our BUY rating with a TP of INR475 (based on 20x Sep'28E EPS).**

Exhibit 6: We trim our EPS estimated by 1-2% for FY27 and FY28

	New		Old		Change	
(INR m)	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Sales	45,522	50,478	44,291	48,869	2.8	3.3
EBITDA	10,847	12,447	10,927	12,601	-0.7	-1.2
PAT	8,265	9,153	8,436	9,268	-2.0	-1.2


Source: Company, MOFSL

Exhibit 7: HMN's P/E (x)



Source: Company, MOFSL

Exhibit 8: Consumer sector's P/E (x)



Source: Company, MOFSL

Financials and valuations

Income Statement

(INR m)

Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E	2029E
Net Sales	**28,805**	**31,881**	**34,057**	**35,781**	**38,092**	**37,795**	**45,522**	**50,478**	**55,820**
Change (%)	8.5	10.7	6.8	5.1	6.5	-0.8	20.4	10.9	10.6
COGS	9,292	10,739	12,014	11,605	11,942	11,380	15,250	16,658	18,141
Gross Profit	**19,513**	**21,142**	**22,044**	**24,176**	**26,150**	**26,415**	**30,272**	**33,821**	**37,678**
Gross Margin (%)	67.7	66.3	64.7	67.6	68.6	69.9	66.5	67.0	67.5
EBITDA	**8,831**	**9,525**	**8,627**	**9,495**	**10,251**	**9,637**	**10,847**	**12,447**	**14,583**
Change (%)	28.1	7.9	-9.4	10.1	8.0	-6.0	12.6	14.7	17.2
Margin (%)	30.7	29.9	25.3	26.5	26.9	25.5	23.8	24.7	26.1
Depreciation	3,669	3,348	2,473	1,859	1,782	1,773	1,839	1,904	1,970
Int. and Fin. Charges	133	51	74	100	93	111	180	95	80
Financial Other Income	703	953	689	468	681	851	870	925	925
Profit before Taxes	**5,731**	**7,079**	**6,770**	**8,005**	**9,057**	**8,603**	**9,699**	**11,373**	**13,459**
Change (%)	46.9	23.5	-4.4	18.2	13.1	-5.0	12.7	17.3	18.3
Margin (%)	19.9	22.2	19.9	22.4	23.8	22.8	21.3	22.5	24.1
Tax	1,142	-1,487	421	667	911	708	2,027	2,843	3,365
Tax Rate (%)	19.9	-21.0	6.2	8.3	10.1	8.2	20.9	25.0	25.0
Adjusted PAT	**6,680**	**7,338**	**6,805**	**7,876**	**8,853**	**8,565**	**8,265**	**9,153**	**10,705**
Change (%)	34.5	9.8	-7.3	15.7	12.4	-3.3	-3.5	10.8	17.0
Margin (%)	23.2	23.0	20.0	22.0	23.2	22.7	18.2	18.1	19.2
Non-rec. (Exp)/Income	-2,133	1,030	-531	-635	-826	-813	-644	-663	-663
Reported PAT	**4,547**	**8,368**	**6,274**	**7,241**	**8,027**	**7,753**	**7,620**	**8,490**	**10,042**

Balance Sheet

(INR m)

Y/E March	2021	2022	2023	2023	2025	2026	2027E	2028E	2028E
Share Capital	445	441	441	437	437	437	437	437	437
Reserves	17,182	20,325	22,587	24,029	26,511	28,803	31,404	34,219	37,932
Net Worth	**17,626**	**20,766**	**23,028**	**24,466**	**26,948**	**29,240**	**31,841**	**34,656**	**38,368**
Minority Interest	-9	-23	100	111	-14	-15	-66	-106	-158
Loans	919	2,637	736	657	621	1,224	1,174	1,124	1,074
Deferred Liability	42	-2,763	-3,502	-4,271	-5,345	-6,321	-6,321	-6,321	-6,321
Capital Employed	**18,578**	**20,617**	**20,361**	**20,964**	**22,209**	**24,127**	**26,627**	**29,353**	**32,963**
Goodwill on consolidation	0	242	682	682	682	682	0	0	0
Gross Block	29,858	35,759	37,238	38,369	39,674	40,979	42,284	43,589	44,894
Less: Accum. Depn.	18,540	22,561	25,466	27,915	30,495	32,791	32,032	33,936	35,905
Net Fixed Assets	**11,318**	**13,198**	**11,772**	**10,455**	**9,179**	**8,189**	**10,253**	**9,654**	**8,989**
Capital WIP	64	31	63	75	133	8	0	0	0
Investments	**2,553**	**3,027**	**2,934**	**4,415**	**6,757**	**7,810**	**10,310**	**12,810**	**15,310**
Curr. Assets, L&A	**11,261**	**11,240**	**12,011**	**12,791**	**13,346**	**14,881**	**15,683**	**17,266**	**19,848**
Inventory	3,005	3,576	3,280	3,234	3,081	3,996	4,813	5,337	5,901
Account Receivables	2,318	3,209	4,146	4,942	4,513	3,433	4,073	4,447	4,841
Cash and cash equivalents	3,604	1,160	1,848	2,014	2,729	4,098	3,076	3,366	4,566
Others	2,335	3,295	2,738	2,601	3,023	3,354	3,722	4,116	4,540
Curr. Liab. and Prov.	**6,618**	**7,119**	**7,100**	**7,454**	**7,888**	**7,442**	**9,619**	**10,377**	**11,184**
Account Payables	3,507	4,087	4,072	4,546	4,546	4,356	5,837	6,376	6,944
Other Liabilities	1,453	1,316	1,470	1,652	2,296	1,782	1,910	2,052	2,210
Provisions	1,658	1,717	1,558	1,256	1,046	1,304	1,871	1,949	2,031
Net Current Assets	**4,643**	**4,120**	**4,912**	**5,336**	**5,459**	**7,439**	**6,064**	**6,889**	**8,664**
Application of Funds	**18,579**	**20,617**	**20,362**	**20,964**	**22,209**	**24,127**	**26,627**	**29,353**	**32,963**

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E	2028E
Basic (INR)									
EPS	**15.0**	**16.6**	**15.4**	**18.0**	**20.3**	**19.6**	**18.9**	**21.0**	**24.5**
Cash EPS	23.3	24.2	21.0	22.3	24.4	23.7	23.1	25.3	29.0
BV/Share	39.7	47.1	52.2	56.1	61.7	67.0	72.9	79.4	87.9
DPS	8.0	8.0	8.0	9.5	10.0	10.0	11.5	13.0	14.5
Payout %	53.2	48.1	51.9	52.6	49.3	51.0	60.7	62.0	59.1
Valuation (x)									
P/E	25.8	23.3	25.2	21.5	19.1	19.8	20.5	18.5	15.8
Cash P/E	31.2	30.0	34.6	32.6	29.8	30.7	31.4	28.7	25.0
EV/Sales	11.0	10.0	9.3	8.7	8.1	8.1	6.7	6.0	5.4
EV/EBITDA	36.0	33.5	36.7	32.8	30.1	31.8	28.1	24.3	20.5
P/BV	18.3	15.5	13.9	13.0	11.8	10.9	10.0	9.2	8.3
Dividend Yield (%)	2.1	2.1	2.1	2.4	2.6	2.6	3.0	3.4	3.7
Return Ratios (%)									
RoE	37.3	38.2	31.1	33.2	34.4	30.5	27.1	27.5	29.3
RoCE	24.1	44.0	31.3	36.0	38.1	34.5	30.8	30.7	32.6
RoIC	27.7	52.0	36.2	46.7	56.3	58.2	56.0	59.9	72.0
Working Capital Ratios									
Debtor (Days)	29	37	44	50	43	33.2	32.7	32.2	31.7
Asset Turnover (x)	1.6	1.5	1.7	1.7	1.7	1.6	1.7	1.7	1.7
Leverage Ratio									
Debt/Equity (x)	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Cash Flow Statement

(INR m)

Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E	2028E
OP/(loss) before Tax	5,689	6,880	6,696	7,908	8,939	8,461	9,699	11,373	13,459
Depreciation	3,670	3,348	2,473	1,859	1,782	1,773	1,839	1,904	1,970
Other non-operating income	-500	-1,321	-90	-277	-313	-1,414	0	0	0
Interest Paid	133	51	74	100	93	111	180	95	80
Direct Taxes Paid	-865	-1,426	-1,170	-1,463	-1,848	-1,719	-2,027	-2,843	-3,365
(Incr)/Decr in WC	1,088	-1,094	-493	-337	305	793	-1,869	-2,728	-2,740
CF from Operations	**9,215**	**6,439**	**7,489**	**7,790**	**8,959**	**8,005**	**7,821**	**7,800**	**9,403**
(Incr)/Decr in FA	-320	-4,802	-301	-288	-434	-304	-1,297	-1,305	-1,305
Free Cash Flow	**8,895**	**1,636**	**7,188**	**7,502**	**8,525**	**7,701**	**6,524**	**6,495**	**8,098**
(Pur)/Sale of Investments	-2,268	2,226	-917	-1,896	-3,149	-1,694	-319	-334	-376
Others	2,668	-2,285	494	190	336	907	-1,967	-40	-52
CF from Invest.	**80**	**-4,861**	**-725**	**-1,994**	**-3,247**	**-1,091**	**-3,582**	**-1,679**	**-1,733**
Change in Equity	0	-2,001	-10	0	0	0	0	0	0
(Incr)/Decr in Debt	139	1,651	-1,901	-133	-150	-202	-50	-50	-50
Dividend Paid	-3,747	-3,556	-3,529	-3,492	-3,492	-5,238	-5,020	-5,675	-6,329
Others	-3,274	-116	-636	-2,005	-1,354	-105	-192	-107	-92
CF from Fin. Activity	**-6,882**	**-4,021**	**-6,076**	**-5,630**	**-4,996**	**-5,545**	**-5,261**	**-5,831**	**-6,471**
Incr/Decr of Cash	**2,413**	**-2,444**	**688**	**166**	**715**	**1,369**	**-1,022**	**290**	**1,199**
Add: Opening Balance	1,191	3,604	1,160	1,848	2,014	2,729	4,098	3,076	3,366
Closing Balance	**3,604**	**1,160**	**1,848**	**2,014**	**2,729**	**4,098**	**3,076**	**3,366**	**4,566**

E: MOSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.